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Abstract 
Combining oral PI3K inhibitors with immunochemotherapy for indolent B-cell lymphoma has been associ- 
ated with toxicity. In the Phase III CHRONOS-4 safety run-in, 21 patients received intravenous copanlisib 
plus rituximab-based immunochemotherapy. There were no dose-limiting toxicities, and preliminary objective 
response rates were 90% to 100%. Copanlisib is the first PI3K inhibitor to demonstrate safe, tolerable, and 
effective combinability with immunochemotherapy, with evaluation ongoing. 
Background: When treating indolent B-cell lymphoma, combining continuously administered oral phosphatidylinosi- 
tol 3-kinase (PI3K) inhibitors with immunochemotherapy has been associated with toxicity. CHRONOS-4 (Phase III; 
NCT02626455) investigates the intravenous, intermittently administered pan-class I PI3K inhibitor copanlisib in combi- 
nation with rituximab plus bendamustine (R-B) or rituximab plus cyclophosphamide, doxorubicin, vincristine, and 
prednisone (R-CHOP) in patients with relapsed indolent B-cell lymphoma. We report safety run-in results. Patients and 
Methods: Patients aged ≥18 years with relapsed CD20-positive indolent B-cell lymphoma received copanlisib (45 mg, 
increasing to 60 mg if no dose-limiting toxicities) weekly on an intermittent schedule with R-B or R-CHOP. Primary objec- 
tive was to identify a recommended Phase III dose (RP3D). We also assessed objective response, safety, and tolerability. 
Results: Ten patients received copanlisib plus R-B and 11 received copanlisib plus R-CHOP. No dose-limiting toxici- 
ties were reported; RP3D was 60 mg. All patients had ≥1 treatment-emergent adverse event (TEAE), most commonly 
(all grade/grade 3/4) for copanlisib plus R-B: decreased neutrophil count (80%/50%), nausea (70%/0%), decreased 
platelet count (60%/10%), hyperglycemia (60%/50%); for copanlisib plus R-CHOP: hyperglycemia (82%/64%), hyper- 
tension (73%/64%), decreased neutrophil count (64%/64%). Two and 8 patients had serious TEAEs with copanlisib plus 
R-B and R-CHOP, respectively. Among evaluable patients, objective response rates were 90% (5 complete, 4 partial) 
and 100% (3 complete, 7 partial) with copanlisib plus R-B and R-CHOP, respectively. Conclusion: Copanlisib is the 
first PI3K inhibitor to demonstrate safe, tolerable, and effective combinability with immunochemotherapy in patients with 
relapsed indolent B-cell lymphoma at full dose (60 mg). Further evaluation is ongoing. 
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Phosphatidylinositol 3-kinase (PI3K) signaling is often dysregu-
lated in indolent B-cell lymphomas. 1 Patients with indolent disease
typically respond to first-line immunochemotherapy, but the disease
course is characterized by continuing relapses, shorter durations of
response or remission, and risk of transformation into aggressive
lymphoma. 2 , 3 Several single-agent PI3K-isoform-specific inhibitors
are in development or have been approved for the treatment of
relapsed or refractory indolent B-cell lymphoma, including oral
inhibitors of PI3K- δ, 4-6 an oral inhibitor of PI3K- δ/PI3K- γ , 7 and
copanlisib, 8 an intravenous, intermittently administered pan-PI3K
inhibitor with predominant activity against the PI3K- α/PI3K- δ
isoforms. 9 , 10 
Copanlisib received approval from the US Food and Drug
Administration in the USA and in Taiwan as monotherapy for
adult patients with relapsed indolent follicular lymphoma who have
received at least 2 systemic therapies, based on the results from
a Phase II study. 11 In this study, a dose of copanlisib 60 mg was
administered to patients intravenously over a 1-hour infusion, on an
intermittent schedule of days 1, 8, and 15 of a 28-day cycle, 11 which
is the approved dose for copanlisib. Copanlisib has demonstrated
target engagement and PI3K pathway modulation and inhibition in
patients with lymphoma and solid tumors. 12 In pooled safety data
from 364 patients with hematologic malignancies receiving treat-
ment with copanlisib in 8 Phase I and II studies, there were no
late-onset toxicities or worsening of severity of treatment-emergent
adverse events (TEAEs) and few severe gastrointestinal TEAEs. 13 
The Phase III CHRONOS-3 study recently identified copanlisib
as the first PI3K inhibitor to be safely combined with rituximab,
and the first to demonstrate broad and superior efficacy in combi-
nation with rituximab in patients with relapsed indolent B-cell
lymphoma. 14 Combining PI3K inhibitors with immunochemother-
apy (rituximab plus bendamustine [R-B], or rituximab plus
cyclophosphamide, doxorubicin, vincristine, and prednisone [R-
CHOP]) in patients with indolent B-cell lymphoma who have
progressed on rituximab-based treatment is an ongoing subject of
investigation in this area of high unmet medical need. However, the
continuous administration of the orally administered PI3K inhibitor
idelalisib in combination with rituximab-based immunochemother-
apy has been associated with severe toxicity, such as autoimmune
dysfunction, opportunistic infections, diarrhea, and colitis, leading
to the discontinuation of several clinical trials of this combination
approach in patients with indolent B-cell lymphoma. 15 
We present results from the initial safety run-in (SRI) of
CHRONOS-4, a Phase III, randomized, double-blind, placebo-
controlled study to evaluate the safety, tolerability, and clinical
indicators of efficacy of copanlisib in combination with standard
immunochemotherapy in patients with relapsed indolent B-cell
lymphoma. 
Patients and Methods 
This study was conducted in accordance with Good Clini-
cal Practice guidelines and applicable local laws and regulations,
and under the guiding principles detailed in the Declaration of
Helsinki. The study protocol and all amendments were reviewedand approved by each site’s institutional ethical committee or review
board. All participants provided written, informed consent. 
Study Design 
CHRONOS-4 (NCT02626455) is a Phase III, randomized,
double-blind, placebo-controlled study conducted in 2 parts: the
SRI ( Figure 1 ) and a subsequent Phase III part (Supplementary
Figure 1). The primary objective of the SRI was to determine the
recommended Phase III dose of copanlisib in combination with
standard immunochemotherapy (R-B or R-CHOP) to be used in
the subsequent Phase III part of the study. Secondary objectives of
the SRI were to evaluate the radiologic and clinical indicators of
treatment efficacy, and the safety and tolerability of copanlisib in
combination with R-B or R-CHOP. 
In the SRI, copanlisib dosing was based on an open-label, 2-
dose level, 3 + 3 design. The 2 treatment combinations of copan-
lisib (with either R-B or R-CHOP) were each tested at 2 copanlisib
dose levels (a first level of 45 mg and a second level of 60 mg) for
safety and tolerability. It was planned that a minimum of 3 and
a maximum of 6 patients were to be evaluable for dose-limiting
toxicities (DLTs) per dose level. The design of the dose-finding steps
for copanlisib and definitions of DLTs are shown in Supplementary
Figure 2. Three patients were initially planned to receive copanlisib
45 mg, and dosing was escalated to 60 mg if no DLTs were observed
in the initial cohort treated with 45 mg. All patients were evaluated
for the occurrence of DLTs during the first treatment cycle; treat-
ment was to be discontinued in any patient experiencing a DLT in
the first cycle. Patients not fully evaluable for occurrence of DLTs
during the first cycle of therapy were replaced. 
Patients treated in the SRI who did not experience a DLT
in the first cycle and who, in the investigator’s opinion, could
benefit from further treatment could continue combination therapy
for a maximum of 6 cycles followed by copanlisib monotherapy
at the same dose of copanlisib that had been administered with
immunochemotherapy. The maximum duration of treatment with
copanlisib was 12 months (including combination therapy and
monotherapy). Patients with benefit who remained on treatment
with copanlisib in combination with R-B or R-CHOP after the first
cycle were evaluated for treatment safety, tolerability, and efficacy. 
Copanlisib was administered as a 1-hour intravenous infusion
on days 1, 8, and 15 of a 28-day cycle in combination with
R-B, or days 1 and 8 of a 21-day cycle with R-CHOP for
≤6 cycles. In the R-B combination, rituximab was administered
intravenously at a dose of 375 mg/m 2 of body surface area on day
1 of each cycle, and bendamustine was administered intravenously
at a dose of 90 mg/m 2 of body surface area on days 1 and 2 of
each cycle. In the R-CHOP combination, rituximab was admin-
istered intravenously at a dose of 375 mg/m 2 of body surface area
on day 2 of each cycle along with intravenous cyclophosphamide
750 mg/m 2 , intravenous doxorubicin 50 mg/m 2 , and intravenous
vincristine 1.4 mg/m 2 (maximum dose of vincristine 2 mg), and oral
prednisone or prednisolone 100 mg daily from day 2 to day 6 of
each cycle. From cycle 7, copanlisib was administered as monother-
apy on days 1, 8, and 15 of a 28-day cycle, irrespective of which
immunochemotherapy regimen was received during cycles 1 to 6.
The maximum duration of copanlisib therapy was 12 months. Clinical Lymphoma, Myeloma and Leukemia 2021 e887 
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Figure 1 Study design of the CHRONOS-4 Phase III study—safety run-in. 
CHOP treatment includes cyclophosphamide 750 mg/m 2 i.v., doxorubicin 50 mg/m 2 i.v., and vincristine 1.4 mg/m 2 i.v. 
(maximum dose 2.0 mg) on day 2 of a 21-day cycle, and prednisone 100 mg tablets on days 2 to 6 of a 21-day cycle. 
Abbreviations: B = bendamustine; CHOP = rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; 
i.v. = intravenous; R = rituximab; R-B = rituximab plus bendamustine; R-CHOP = rituximab plus cyclophosphamide, 
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e888 Dosing was not to be reduced for rituximab or any components
of CHOP or bendamustine in the first treatment cycle; except for
rituximab, dose reductions were otherwise permitted from cycle 2
onwards according to local standards of care, prescribing informa-
tion, and the investigator’s experience. After cycle 1, the copanlisib
dose could be reduced from 60 mg to 45 mg, and further to 30 mg, if
toxicities occurred. The use of myeloid growth factors in the prophy-
lactic and therapeutic setting was allowed during study treatment
based on local standard of care and at the investigator’s discretion. 
Patients 
Eligible patients were aged ≥18 years with a histologically
confirmed diagnosis of CD20-positive indolent B-cell lymphoma
(histology was limited to follicular lymphoma grades 1-3a, marginal
zone lymphoma [splenic, nodal, or extranodal], small lympho-
cytic lymphoma, or lymphoplasmacytic lymphoma/Waldenström
macroglobulinemia), relapsed or progressed after 1 to 3 lines of
therapy, including rituximab and/or rituximab biosimilars, or other
anti-CD20 monoclonal antibody-based immunochemotherapy and
alkylating agents. Patients who experienced a lack of response
or progression within 6 months of the last date of anti-CD20Clinical Lymphoma, Myeloma and Leukemia 2021 monoclonal antibody-containing treatment were ineligible. Key
additional inclusion and exclusion criteria are presented in Supple-
mentary Table 1. 
Endpoints and Assessments 
The primary endpoint in the SRI was the occurrence of DLTs,
which informed the primary objective of identifying the recom-
mended Phase III dose (Supplementary Figure 2). The frequency
and intensity of adverse events (AEs) were carefully monitored,
together with the occurrence of new or unexpected AEs. Safety was
assessed throughout the study and included the following secondary
endpoints: toxicity/AEs; vital signs; clinical laboratory variables;
and review of concomitant medications. AEs were reported and
graded according to the Common Terminology Criteria for Adverse
Events version 4.03. Secondary outcome measures were evaluation
of indicators of treatment efficacy and safety and tolerability of
copanlisib in combination with R-B or R-CHOP, assessed by the
number of patients with TEAEs. 
Screening tests were performed within 7 days before planned
day 1 of cycle 1 and included a complete physical examination
and laboratory values. At each visit before treatment, patients were




































evaluated for opportunistic infections, including any new onset or
worsening of pulmonary symptoms (ie, cough, dyspnea, or fever).
Cytomegalovirus was monitored by polymerase chain reaction on
day 1 of every cycle during combination therapy. For patients with
signs of cytomegalovirus, CD4 levels were monitored. 
On copanlisib infusion days, blood pressure was measured
before, during, and after the infusion. Predose blood pressure
values had to be < 150/90 mm Hg before copanlisib was
administered. In addition, on day 1 in the R-B treatment
group, blood pressure was measured during and after rituximab
infusion. 
On copanlisib infusion days, blood glucose was measured before
dosing and at the end of the copanlisib infusion, at the end of the
rituximab infusion, and at the end of the bendamustine infusion
if the patient received corticosteroid medication before bendamus-
tine infusion. On the day after the first copanlisib infusion of
each cycle, patients receiving corticosteroid medication before the
bendamustine or rituximab infusions had a blood glucose test within
30 minutes before bendamustine or rituximab infusions and at the
end of the infusions . 
Tumors were assessed radiologically at screening and every
12 weeks during treatment using contrast-enhanced computed
tomography, magnetic resonance imaging, or positron emission 




Age (y), median (range) 62 (41-8
ECOG performance status 
0 5 (50.0
1 5 (50.0
Histology of lymphoma 
Follicular lymphoma 7 (70.0
Extranodal marginal zone lymphoma or MALT lymphoma 1 (10.0
Lymphoplasmacytic lymphoma 1 (10.0
Waldenström macroglobulinemia 1 (10.0













Data are presented as n (%) unless otherwise indicated. 
Abbreviations: ECOG = Eastern Cooperative Oncology Group; MALT = mucosa-associated lymphoid tiss
bicin, vincristine, and prednisone; SRI = safety run-in. 
a Data for 3 patients in the R-B SRI were missing/not applicable. 
b Data for 1 patient in the R-B SRI were missing/not applicable. tomography-computed tomography. Assessment of tumors in
patients with Waldenström macroglobulinemia who did not have
radiologically measurable lesions at screening was performed by
laboratory and clinical tests. Response to treatment was assessed
by the investigator according to the Lugano classification, 16 or
according to the Owen Criteria 17 for patients with Waldenström
macroglobulinemia. 
Statistical Analysis 
Safety data from the SRI were summarized by dose level. All
patients who had received at least 1 dose of study treatment were
included in analyses of safety (full analysis set). 
Results 
Patients and Treatment 
Ten patients were enrolled and treated in the copanlisib plus
R-B SRI, 7 with follicular lymphoma, 1 with lymphoplasmacytic
lymphoma, 1 with Waldenström macroglobulinemia, and 1 with
extranodal marginal zone lymphoma ( Table 1 ); 3 patients received
copanlisib at the 45 mg dose level and 7 patients received copan-
lisib at the 60 mg dose level. Eleven patients were enrolled and
treated in the copanlisib plus R-CHOP SRI, all with follicular




R-CHOP SRI (N = 11) 
Total (N = 21) 
) 5 (45.5) 13 (61.9) 
2) 64 (46-78) 63 (41-82) 
) 8 (72.7) 13 (61.9) 
) 3 (27.3) 8 (38.1) 
) 11 (100) 18 (85.7) 
) 0 1 (4.8) 
) 0 1 (4.8) 
) 0 1 (4.8) 
) 0 5 (23.8) 
) 7 (63.6) 9 (42.9) 
4 (36.4) 4 (19.0) 
) 2 (18.2) 3 (14.3) 
1 (9.1) 1 (4.8) 
) 3 (27.3) 5 (23.8) 
) 5 (45.5) 11 (52.4) 
) 9 (81.8) 15 (71.4) 
) 2 (18.2) 5 (23.8) 
) 0 1 (4.8) 
ue; R-B = rituximab plus bendamustine; R-CHOP = rituximab plus cyclophosphamide, doxoru- 
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Table 2 Overview of TEAEs (Safety Analysis Set) 
Copanlisib Plus R-B SRI (N = 10) Copanlisib Plus R-CHOP SRI (N = 11) 
Any TEAE 10 (100) 11 (100) 
Grade ≥3 7 (70.0) 10 (90.9) 
Any copanlisib-related TEAE 9 (90.0) 11 (100) 
Any R-B- or R-CHOP-related TEAE 10 (100) 11 (100) 
Any serious TEAE 2 (20.0) 8 (72.7) 
Grade ≥3 2 (20.0) 6 (54.5) 
Copanlisib-related 2 (20.0) 8 (72.7) 
Data are presented as n (%). 
Abbreviations: AE = adverse event; R-B = rituximab plus bendamustine; R-CHOP = rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; SRI = safety run-in; TEAE = treatment- 











































































e890 and 6 patients received copanlisib at the 60 mg dose level. Eighty
percent of patients in the R-B SRI and 45% of patients in the R-
CHOP SRI were female; the median ages of the groups were 62 and
64 years, respectively ( Table 1 ). Before study enrollment, 60% of
patients in the R-B SRI and 82% of patients in the R-CHOP SRI
had received 1 line of therapy ( Table 1 ). 
In the R-B SRI, the median number of copanlisib treatment
cycles was 3 (range, 2-5), and the mean dose of copanlisib admin-
istered per cycle was 135.2 mg (range, 80-180 mg). Eight patients
had dose interruptions or delays with copanlisib therapy, which were
caused by AEs. Copanlisib dose reduction occurred in 1 patient
receiving 45 mg and no patients receiving 60 mg in the R-B SRI.
At the time of data cut-off, no patients had yet received copanlisib
monotherapy following the protocol-specified ≤6 cycles of R-B.
The mean dose of rituximab was 375 mg/m 2 per cycle (range, 375-
375 mg/m 2 ), and the mean dose of bendamustine was 82.0 mg/m 2
per cycle (range, 67.5-90.0 mg/m 2 ); overall, patients received a
median of 3.6 cycles of R-B (range, 2-5). Seven patients had dose
interruptions or delays from R-B therapy, which were caused by
AEs. At the time of data cut-off, 6 patients in the R-B SRI were
still receiving treatment with copanlisib. 
In the R-CHOP SRI, the median number of copanlisib cycles
was 8 (range, 2-15), and the mean copanlisib dose administered
per cycle was 106.0 mg (range, 68-136 mg). Nine patients had dose
interruptions or delays with copanlisib therapy, which were caused
by AEs. Copanlisib dose reduction occurred in 1 patient receiving
45 mg and no patients receiving 60 mg in the R-CHOP SRI. Six
patients received copanlisib monotherapy following the protocol-
specified ≤6 cycles of R-CHOP. Mean chemotherapy doses per cycle
were as follows: rituximab 380.5 mg/m 2 (range, 367-428 mg/m 2 ),
cyclophosphamide 750 mg/m 2 (range, 750-750 mg/m 2 ), doxoru-
bicin 50 mg/m 2 (range, 50-50 mg/m 2 ), vincristine 1.4 mg/m 2
(range, 1-2 mg/m 2 ), and prednisone/prednisolone 118.5 mg (range,
58-340 mg). Patients received a median of 6 cycles of R-
CHOP (range, 2-6). Dose interruptions or delays were recorded
in 5 patients for rituximab, 4 patients each for cyclophos-
phamide, doxorubicin, and vincristine, and 3 patients for
prednisone/prednisolone; AEs were the primary cause of all
interruptions and delays. At the time of data cut-off, 3
patients in the R-CHOP SRI were still receiving treatment with
copanlisib. Clinical Lymphoma, Myeloma and Leukemia 2021 Safety 
No DLTs were reported at either dose of copanlisib (45 or 60 mg)
in the R-B SRI or the R-CHOP SRI. The recommended Phase
III dose of copanlisib was therefore defined as 60 mg for both
immunochemotherapy combinations. 
All patients in both treatment groups (100%) experienced at least
1 TEAE ( Table 2 ). Nine patients (90%) in the R-B SRI and 11
patients (100%) in the R-CHOP SRI experienced TEAEs consid-
ered related to copanlisib, and all patients in both groups experi-
enced AEs considered related to R-B or R-CHOP. Serious TEAEs
were recorded in 2 patients (20%) in the R-B SRI and 8 patients
(73%) in the R-CHOP SRI; all were considered related to study
treatment ( Table 2 ). 
The most common TEAEs of any grade in patients receiving
copanlisib plus R-B were decreased neutrophil count (80%), nausea
(70%), decreased platelet count (60%), and hyperglycemia (60%);
in patients receiving copanlisib plus R-CHOP, the most common
all-grade TEAEs were hyperglycemia (82%), hypertension (73%),
and decreased neutrophil count (64%) ( Table 3 ). 
TEAEs of worst grade 3 or 4 occurring in 2 or more patients
receiving copanlisib plus R-B were decreased neutrophil count and
hyperglycemia (5/10 [50%] each), decreased lymphocyte count
(3/10 [30%]), and decreased white blood cell count and hyper-
tension (2/10 [20%] each). In patients receiving copanlisib plus
R-CHOP, the TEAEs of worst grade 3 or 4 occurring in 2 or
more patients were hyperglycemia, hypertension, and decreased
neutrophil count (7/11 [64%] each), decreased lymphocyte count
(3/11 [27%]), and febrile neutropenia, hypokalemia, lung infection,
decreased platelet count, and decreased white blood cell count (2/11
[18%] each) ( Table 3 ). 
The 2 serious TEAEs in the R-B SRI were eosinophilia and lung
infection, occurring in 1 patient receiving copanlisib 45 mg; the
case of eosinophilia was considered related to copanlisib, and the
case of lung infection was considered related to copanlisib and R-
B therapy. No patients receiving copanlisib 60 mg plus R-B had
serious TEAEs. Serious TEAEs in the R-CHOP SRI occurring in 2
or more patients were lung infection (3 patients [27%], all receiving
copanlisib 60 mg), febrile neutropenia (2 patients [18%], 1 receiving
copanlisib 45 mg and 1 receiving 60 mg), fever (2 patients [18%],
1 receiving copanlisib 45 mg and 1 receiving 60 mg), and hyper-
glycemia (2 patients [18%], both receiving copanlisib 60 mg). In
Matthew J. Matasar et al 
Table 3 TEAEs Occurring in ≥2 Patients in Either Group 
Copanlisib Plus R-B SRI 
(N = 10) 
Copanlisib Plus R-CHOP SRI 
(N = 11) 
All Grades Grade 3 or 4 All Grades Grade 3 or 4 
Blood and lymphatic system disorders 
Anemia 4 (40.0) 0 5 (45.5) 1 (9.1) 
Febrile neutropenia 0 0 2 (18.2) 2 (18.2) 
Gastrointestinal disorders 
Nausea 7 (70.0) 0 4 (36.4) 0 
Mucositis oral 5 (50.0) 1 (10.0) 3 (27.3) 0 
Diarrhea 4 (40.0) 1 (10.0) 6 (54.5) 1 (9.1) 
Constipation 3 (30.0) 0 3 (27.3) 0 
Decreased appetite 2 (20.0) 0 0 0 
Other gastrointestinal disorders 0 0 2 (18.2) 1 (9.1) 
Vomiting 2 (20.0) 0 0 0 
General disorders and administration site conditions 
Fatigue 5 (50.0) 0 4 (36.4) 0 
Fever 4 (40.0) 0 5 (45.5) 0 
Flu-like symptoms 0 0 3 (27.3) 1 (9.1) 
Immune system disorders 
Allergic reaction 2 (20.0) 0 2 (18.2) 1 (9.1) 
Infections and infestations 
Lung infection 1 (10.0) 1 (10.0) 3 (27.3) 2 (18.2) 
Other infections and infestations 0 0 2 (18.2) 1 (9.1) 
Upper respiratory infection 0 0 3 (27.3) 0 
Urinary tract infection 0 0 2 (18.2) 0 
Investigations 
Decreased neutrophil count 8 (80.0) 5 (50.0) 7 (63.6) 7 (63.6) 
Decreased platelet count 6 (60.0) 1 (10.0) 6 (54.5) 2 (18.2) 
Decreased white blood cell count 4 (40.0) 2 (20.0) 2 (18.2) 2 (18.2) 
Increased ALT 3 (30.0) 0 0 0 
Increased AST 3 (30.0) 0 0 0 
Decreased lymphocyte count 3 (30.0) 3 (30.0) 3 (27.3) 3 (27.3) 
Metabolism and nutrition disorders 
Hyperglycemia 6 (60.0) 5 (50.0) 9 (81.8) 7 (63.6) 
Hypokalemia 0 0 2 (18.2) 2 (18.2) 
Musculoskeletal and connective tissue disorders 
Other musculoskeletal and connective tissue disorders 0 0 2 (18.2) 0 
Nervous system disorders 
Dysgeusia 3 (30.0) 0 2 (18.2) 0 
Headache 3 (30.0) 0 3 (27.3) 0 
Peripheral sensory neuropathy 0 0 3 (27.3) 0 
Respiratory, thoracic, and mediastinal disorders 
Cough 0 0 5 (45.5) 0 
Dyspnea 0 0 2 (18.2) 0 
Skin and subcutaneous tissue disorders 
Rash maculopapular 4 (40.0) 0 1 (9.1) 0 
Pruritus 3 (30.0) 0 2 (18.2) 0 
Vascular disorders 
Hypertension 2 (20.0) 2 (20.0) 8 (72.7) 7 (63.6) 
Hypotension 1 (10.0) 0 2 (18.2) 1 (9.1) 
Data are presented as n (%). 
Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; R-B = rituximab plus bendamustine; R-CHOP = rituximab plus cyclophosphamide, doxorubicin, vincristine, and 
prednisone; SRI = safety run-in; TEAE = treatment-emergent adverse event. 
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Table 4 Tumor Response Evaluation (Investigator Assessment; Full Analysis Set With Postbaseline Tumor Assessment) 
Copanlisib Plus R-B SRI (N = 10) Copanlisib Plus R-CHOP SRI (N = 10 a ) 
Best overall response 
Complete response 5 (50.0) b [18.7, 81.3] 3 (30.0) [6.7, 65.2] 
Partial response 4 (40.0) c [12.2, 73.8] 7 (70.0) b [34.8, 93.3] 
Stable disease 1 (10.0) [0.3, 44.5] 0 [0.0, 30.8] 
Progressive disease 0 [0.0, 30.8] 0 [0.0, 30.8] 
Objective response rate 9 (90.0) [55.5, 99.7] 10 (100) [69.2, 100] 
Data are presented as n (%) [95% CI]. 
Abbreviations: CI = confidence interval; R-B = rituximab plus bendamustine; R-CHOP = rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; SRI = safety run-in. 
a 11 patients were treated, but 1 patient was not included because their first postbaseline tumor assessment was reached after the data cut-off date. 
b 1 patient had their first postbaseline tumor assessment outside of the protocol-required 12-week ( ± 1 week) assessment period. 









































































e892 the R-CHOP SRI, 2 serious TEAEs of lung infection were consid-
ered related to copanlisib, and 1 was considered related to R-CHOP.
The serious TEAEs of febrile neutropenia, fever, and hyperglycemia
were considered related to R-CHOP, with fever and hyperglycemia
also considered related to copanlisib. 
In the R-B SRI, 4 patients experienced TEAEs leading to discon-
tinuation of copanlisib treatment, and 3 patients had TEAEs
leading to discontinuation of R-B. In the R-CHOP SRI, 5 patients
experienced TEAEs leading to discontinuation of copanlisib treat-
ment, and 3 patients had TEAEs leading to discontinuation of
R-CHOP. 
One patient (10%) experienced a TEAE of special interest (grade
3 pneumonitis) in the R-CHOP SRI; no patients experienced
pneumonitis in the R-B SRI or colitis in either treatment group. 
No patients in either treatment group received granulocyte
colony-stimulating factor. 
Efficacy 
Response to treatment was evaluated in the 10 patients in the R-B
SRI and in 10 of the 11 patients in the R-CHOP SRI. Overall, 5 and
3 patients achieved complete responses in the R-B and R-CHOP
SRIs, respectively, with 4 and 7 patients achieving partial responses
( Table 4 ); the objective response rates were 90% with copanlisib
plus R-B and 100% with copanlisib plus R-CHOP. One patient in
the R-B SRI had stable disease, and 1 patient receiving copanlisib
plus R-CHOP was not included in the efficacy analysis because the
first postbaseline tumor assessment, at which a partial response was
achieved, was after the date of data cut-off. 
Discussion 
This SRI of the CHRONOS-4 study evaluated the safety and
tolerability of copanlisib in combination with R-B or R-CHOP in
patients with relapsed indolent B-cell lymphoma who had relapsed
after 1 to 3 lines of treatment, including rituximab and alkylating
agents. The recommended Phase III dose of copanlisib was defined
as 60 mg for both immunochemotherapy combinations, consistent
with the current full dose of copanlisib approved for the treatment of
relapsed follicular lymphoma. 18 Copanlisib was generally well toler-
ated in both immunochemotherapy combinations, and no DLTs or
fatal AEs were reported at either dose of copanlisib (45 or 60 mg) in
either treatment group. Only 2 patients required a copanlisib doseClinical Lymphoma, Myeloma and Leukemia 2021 reduction due to a TEAE; 1 patient in each arm had a dose reduc-
tion from 45 mg to 30 mg. 
At the time of data cut-off, 6 patients in the R-B SRI and
3 patients in the R-CHOP SRI were still receiving study treat-
ment. The most common TEAEs following a median of 3 copan-
lisib treatment cycles in the R-B SRI and 8 in the R-CHOP
SRI were consistent with those reported in previous studies of
copanlisib monotherapy and, overall, included decreased neutrophil
count, nausea, decreased platelet count, hyperglycemia, and hyper-
tension. 11 , 19 Hyperglycemia is a known on-target class effect of
PI3K pathway inhibition 20 and is one of the most common TEAEs
observed in clinical studies of copanlisib monotherapy, usually seen
as a transient, infusion-related effect that has been reported to be
manageable, with blood glucose levels returning to normal levels
within a day of copanlisib infusion. 21 Management of copanlisib-
related hyperglycemia frequently required adequate hydration alone
in the Phase II CHRONOS-1 study in patients with indolent B-cell
lymphoma, with insulin or oral glucose-lowering agents required in
a proportion of patients. 11 Hematologic toxicities in this study are
most likely a consequence of the accompanying immunochemother-
apy regime, having been observed at similar frequencies in other
immunochemotherapy trials. 22 , 23 However, these side effects have
also been observed with targeted PI3K inhibition in malignant B-
cells, as previously reported in several monotherapy studies of differ-
ent agents (copanlisib, all-grade neutropenia 28.9% 19 ; duvelisib,
all-grade neutropenia 28.7% 24 ; umbralisib, grade 3 or 4 neutrope-
nia 8% 5 ). Rituximab alone is also associated with hematologic
AEs in patients with indolent lymphoma, with neutropenia and
thrombocytopenia common events with either rituximab alone
or in combination with chemotherapy. 25 No AEs of colitis were
reported in the SRI of CHRONOS-4, which is encouraging given
the high rates of severe gastrointestinal toxicities and liver enzyme
elevations observed in patients in a Phase II study of idelalisib
plus ofatumumab 26 and a Phase I study of duvelisib plus ritux-
imab or bendamustine/rituximab. 27 The intermittent dose sched-
ule and intravenous administration of copanlisib could explain this
finding, as it results in reduced exposure in the gastrointestinal tract
compared with daily oral regimens. Serious TEAEs were observed
in both SRI treatment groups—1 case of eosinophilia and 1 case
of lung infection considered related to copanlisib—whereas the
remaining serious TEAEs were considered related to combination
































































































therapy or to immunochemotherapy alone. Lung infection has been
reported as a serious TEAE in studies of other PI3K inhibitors in
monotherapy 4 and was observed in a previous report of copanlisib
monotherapy. 11 Opportunistic infections in the respiratory tract and
autoimmune toxicities such as pneumonitis have been reported with
monotherapy with the PI3K inhibitors idelalisib and duvelisib, 28-30 
with a black box warning for fatal and/or severe pneumonitis in
place for both. 6 , 7 Severe opportunistic infections, among other
toxicities, have been observed with idelalisib plus rituximab-based
chemotherapy, leading to the discontinuation of several studies. 15 
Eosinophilia has not been previously reported with copanlisib but
may fall within the expected hematologic toxicity profile of PI3K
inhibitors, as seen with other agents in monotherapy. 31 Longer-term
study of the copanlisib plus R-B or R-CHOP regimens in a larger
number of patients is ongoing to gain a broader view of the safety
profile of each combination; conclusive interpretations are not yet
possible from the few patients evaluated in the CHRONOS-4 SRI. 
Preliminary evaluation of response to copanlisib plus rituximab-
based immunochemotherapy in these small cohorts of patients
demonstrated encouraging evidence of efficacy, with objective
response rates of 90% in the R-B SRI and 100% in the R-CHOP
SRI. 
Conclusion 
Patients with relapsed indolent B-cell lymphoma represent a
population who urgently require additional safe and effective treat-
ment options. Overall, this analysis from the CHRONOS-4 R-B
and R-CHOP SRIs demonstrated no unexpected safety concerns
or DLTs when combining copanlisib with immunochemotherapy.
Copanlisib plus R-B and copanlisib plus R-CHOP were gener-
ally well tolerated, and the safety profiles were consistent with
reports of copanlisib monotherapy and immunochemotherapy.
Copanlisib is the first PI3K inhibitor, including oral agents, to
demonstrate preliminary safe, tolerable, and effective combinabil-
ity with standard immunochemotherapy in this rituximab-sensitive
pretreated population at full dose (60 mg). These results support
further evaluation of copanlisib 60 mg plus R-B or R-CHOP
vs. placebo plus R-B or R-CHOP in the Phase III part of the
CHRONOS-4 study, which is currently ongoing, in order to deter-
mine the superiority of copanlisib vs. placebo in combination with
immunochemotherapy in relapsed indolent B-cell lymphoma. 
Clinical Practice Points 
Combining continuously administered oral phosphatidylinosi-
tol 3-kinase (PI3K) inhibitors (eg, idelalisib and duvelisib) with
rituximab-based immunochemotherapy in patients with indolent B-
cell lymphoma, for whom there is a high unmet need, has been
associated with severe toxicity, such as autoimmune dysfunction,
opportunistic infections, diarrhea, and colitis. Copanlisib is an
intravenous, intermittently administered pan-PI3K inhibitor that is
approved as monotherapy for adult patients with relapsed indolent
follicular lymphoma who have received at least 2 systemic therapies.
The safety run-in of the Phase III CHRONOS-4 study enrolled
patients with relapsed indolent lymphoma who had relapsed
after 1 to 3 lines of treatment; 10 patients received copan-
lisib with rituximab plus bendamustine (R-B) and 11 patientsreceived copanlisib with rituximab plus cyclophosphamide, doxoru-
bicin, vincristine, and prednisone (R-CHOP). The most common
treatment-emergent adverse events in both groups were consistent
with those reported in previous studies of copanlisib monotherapy,
and included decreased neutrophil count, nausea, decreased platelet
count, hyperglycemia, and hypertension. Preliminary efficacy results
demonstrated encouraging evidence of efficacy, with objective
response rates of 90% in patients treated with copanlisib plus R-B
and 100% with copanlisib plus R-CHOP. 
Copanlisib is the first PI3K inhibitor to demonstrate safe, toler-
able, and effective combinability with immunochemotherapy in
patients with relapsed indolent B-cell lymphoma at full dose (60 mg)
and may soon represent a new treatment option in this underserved
population. Further evaluation is ongoing to determine the superi-
ority of copanlisib 60 mg plus R-B or R-CHOP vs. placebo plus R-B
or R-CHOP in patients with relapsed indolent B-cell lymphoma. 
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